CurrentUnitedHealthcarePolicy CS001.T

Ablative Treatment for Spinal Pain

UnitedHealthcare medical policy CS001.T addresses coverage and medical necessity determinations for various ablative treatments for spinal pain (facet, sacroiliac, basivertebral nerve), lists unproven techniques considered not medically necessary, provides definitions, rationale, evidence summaries, and applicable procedure codes. This policy excludes certain state-specific applicability noted in the Application section.

Policy Summary

PayerUnitedHealthcare

PolicyAblative Treatment for Spinal Pain

Policy CodePolicy CS001.T

Change TypeClarified supporting information

Effective DateMar 1, 2026

Next Review Date

Key ActionConfirm state-specific applicability and follow policy coding and medical necessity criteria when determining coverage; document diagnostic medial branch block results and Modic type 1 or 2 changes for BVN RFA where applicable.

SourceLink

POLICY UPDATE CHANGES

Supporting Information updated to reflect the most current Clinical Evidence and References sections.

6Techniques listed as unproven/not medically necessary

6Procedure codes listed for reference

MultipleEvidence sources

Moderate-limitedEvidence quality (per reviews)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

UnitedHealthcare medical policy CS001.T addresses coverage and medical necessity for ablative treatments for spinal pain (facet, sacroiliac, and basivertebral nerve). The policy stance is mixed: it lists several ablative techniques as unproven / not medically necessary because of insufficient evidence, while acknowledging evolving but limited evidence for intraosseous basivertebral nerve (BVN) radiofrequency ablation.

At-a-glance: techniques considered unproven / not medically necessary include Pulsed RFA, Endoscopic RFA/Endoscopic rhizotomy, Cryoablation, Cooled RFA, Chemical ablation (e.g., alcohol, phenol), and Laser ablation (Coverage Rationale). Ablation for sacroiliac joint pain and intraosseous BVN ablation (Intracept) are also designated unproven / not medically necessary due to insufficient evidence (Instructions for Use).

State-specific exclusions: this policy does not apply in specified states; providers should refer to state-specific policy/guideline for Idaho, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, Tennessee, Indiana, and Louisiana as noted in the Application section.

Provider actions: use listed procedure codes for reference only and follow federal/state/contractual requirements when determining coverage; document diagnostic medial branch blocks (with at least 50% relief where referenced) before lumbar facet RFA and, for BVN procedures, document presence of Modic type 1 or 2 changes at L3–S1 as used in trials.

Not Medically Necessary / Unproven Techniques & Evidence Summary

Not medically necessary / Unproven techniques

The following facet joint nerve ablation techniques are unproven and not medically necessary due to insufficient evidence of efficacy:

Pulsed Radiofrequency Ablation of the facet nerves of the cervical, thoracic or lumbar region, sacral nerve root, or dorsal root ganglion
Insufficient evidence to establish safety and efficacy; well-designed RCTs needed (AHRQ, Hayes).
Endoscopic radiofrequency ablation / Endoscopic rhizotomy: Endoscopic radiofrequency ablation/endoscopic rhizotomy
Insufficient evidence; some trials suggest longer-term pain reduction vs percutaneous RFA but further research required.
Cryoablation (cryodenervation, cryoneurolysis, cryosurgery, or cryoanesthesia)
Insufficient evidence; case series and small studies report benefit but lack comparative RCTs.
Cooled Radiofrequency Ablation
Insufficient evidence for facet/SIJ pain; mixed short-term benefits and limited long-term data.

Additional unproven indications (Instructions for Use)

Additional treatments considered unproven and not medically necessary:

Ablation for sacroiliac pain: Ablation for treating sacroiliac pain is unproven and not medically necessary due to insufficient evidence of efficacy.
Evidence for CRFA/CRFA-like approaches shows mixed or limited-quality evidence; further high-quality research needed.
Intraosseous BVN RFA (Intracept): Intraosseous radiofrequency ablation of the basivertebral nerve (e.g., Intracept®) for the treatment of spinal pain is unproven and not medically necessary due to insufficient evidence of efficacy.
Pooled analyses and RCTs report improvements in ODI and pain but are limited by open-label design, industry sponsorship, crossover, and need for independent, long-term comparative trials.

Procedure Codes and Coding Notes

Applicable procedure codes (reference only)mixed

22899	Unlisted procedure, spine [when used to report the Intracept procedure or cooled radiofrequency ablation]
27299	Unlisted procedure, pelvis or hip joint
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (i.e., fluoroscopy or computed tomography)
64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)
64999	Unlisted procedure, nervous system

Coding clarificationCPT

64999

CPT code 64999 is to be used for Pulsed Radiofrequency Ablation. (CPT Assistant, 2016)

Provider Actions & Operational Requirements

Prior Authorization

Coverage determination required per policy

Use the policy coding and medical necessity criteria to determine coverage. Listing of procedure codes is for reference only and does not imply that the listed services are covered or reimbursable under a given benefit plan.

22899
27299
64625
64628
64629
64999

Documentation Required

State-specific policy applicability

This UnitedHealthcare medical policy CS001.T does not apply in the listed states. Refer to the state-specific policy or guideline where noted for coverage determination and procedural guidance.

Clinical Evidence, Guidelines, and Definitions

The evidence base summarized in the policy includes systematic reviews, randomized controlled trials (RCTs), prospective cohort studies, pooled analyses, and health technology assessments. For many modalities (pulsed RFA, endoscopic RFA, cryoablation, cooled RFA, chemical and laser ablation), systematic reviews and technology assessments report insufficient or low-quality evidence and call for larger, well‑designed RCTs with longer-term follow-up (AHRQ, Hayes, and other reviews).

For cooled RFA and cryoablation, available randomized and comparative studies and meta-analyses report mixed short-term benefits for sacroiliac or facet-mediated pain but are limited by small sample sizes, inconsistent techniques, short follow-up, and observational designs; overall conclusions are that evidence is insufficient to establish safety and long-term efficacy (Chou et al. 2021; Cohen et al. 2024; Hayes assessments).

Intraosseous BVN RFA (Intracept) has a more developed but still mixed literature: two RCTs (SMART sham-controlled and INTRACEPT comparing standard care) and pooled/long-term follow-ups report clinically meaningful reductions in ODI and pain scores and durable improvements to 3–5 years in some cohorts, and pooled analyses show decreased opioid and intervention use. However, systematic reviews and assessments (Conger et al. 2021; Hayes 2021/2025; ECRI) note limitations including open-label designs, industry sponsorship, high crossover rates, short safety follow-up in some trials, and need for independent, multicenter, blinded RCTs before definitive conclusions can be drawn.

Overall, the policy characterizes evidence for many ablative modalities as insufficient/unproven, and for BVN RFA as mixed/moderate but limited, warranting further high-quality, non–industry-funded comparative studies.

Evidence	Summary / Key data
Pulsed RFA evidence statement	Insufficient evidence to establish safety and efficacy; AHRQ and Hayes reviews cite limited, low-quality RCTs and need for well-designed trials (small samples, inconsistent methods, lack long-term follow-up).
Endoscopic RFA evidence statement	Insufficient evidence; some trials and a 2024 systematic review/meta-analysis suggest possible longer-term pain reduction vs percutaneous RFA but further large RCTs and longer follow-up needed.
Cryoablation evidence statement	Insufficient evidence; case series and small studies report benefit but comparative RCTs are lacking; limited long-term data.
Cooled RFA evidence statement	Insufficient evidence for facet/SIJ pain; some RCTs show short- to medium-term benefit vs medical management but overall low-quality, small studies and lack of >6-12 month data.
Basivertebral nerve (BVN) intraosseous RFA evidence statement	Mixed evidence: RCTs (SMART, INTRACEPT) and pooled/long-term analyses report clinically meaningful ODI and pain improvements up to 3–5 years and reductions in opioid/use and interventions, but many studies are industry-sponsored, open-label, with crossover and bias concerns; further independent RCTs needed.
SMART trial ODI change at 3 months (per-protocol)	Treatment arm decreased 20.5 points vs sham 15.2 points; responder (≥10-point ODI) 75.6% vs 55.3% (per-protocol).
INTRACEPT multicenter RCT (Khalil et al. 2019) ODI change at 3 months	RFA −25.3 points vs standard care −4.4 points; adjusted difference 20.9 points (p < 0.001); 74.5% vs 32.7% achieved ≥10-point ODI improvement at 3 months.
Pooled/long-term outcomes	Pooled analyses report durable mean ODI and pain improvements at 3–5 years (eg, mean ODI reductions ~28–31 points; NPS reductions ~4.3 points), decreased opioid use and lower subsequent interventions; limitations include open-label design, sponsorship, and crossover.
Hayes assessment	Hayes (2021, updated 2025) found minimal support overall; studies generally poor or fair quality and update found no new evidence to change conclusion.
ECRI assessment	ECRI (2020b updated 2024) noted potential benefits but too few data; multicenter blinded RCTs needed and existing RCTs had small or clinically insignificant differences vs sham.

Cooled Radiofrequency Ablation: the application of continuous high-frequency electrical current to ablate nerve tissue using water-cooled electrodes/probes.

Revision History

03/01/2026clarifiedLatest

clarified: Supporting Information updated to reflect the most current Clinical Evidence and References sections.